BioCentury
ARTICLE | Company News

Ionis, Bayer deal

February 17, 2017 8:40 PM UTC

Ionis will receive a $75 million milestone payment from Bayer tied the development of anticoagulants IONIS-FXIRx (BAY 2306001) and IONIS-FXI-LRx, both Factor XI antisense inhibitor. The partners share rights to IONIS-FXIRx under a 2015 deal and said they have added preclinical candidate IONIS-FXI-LRx to the agreement.

Ionis plans to start a Phase IIb trial next half of IONIS-FXIRx in about 200 patients on hemodialysis with end-stage renal disease (ESRD) and plans to develop IONIS-FXI-LRx through a Phase I trial, which is slated to begin in early 2018. Bayer may then opt to advance either program. If it does, Bayer would be responsible for subsequent development and commercialization and Ionis would be eligible for milestones plus tiered royalties...

BCIQ Target Profiles

Factor XI